HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Familial type V hyperlipoproteinemia with hyper-remnant-like particle-cholesterol accompanied with apolipoprotein E3/E4 phenotype.

Abstract
A 41-year-old woman and her 2 sons had Type V hyperlipoproteinemia. Interestingly, the patient and her younger son had higher levels of remnant-like particle (RLP)-cholesterol than her elder son; the former two had apolipoprotein E phenotype E3/E4, while the latter had E3/E3. Hyper-RLP-ch levels may be associated with the apolipoprotein E4 phenotype. Moreover, after administration of bezafibrate, the patient's triglyceride, RLP-cholesterol and RLP-triglyceride levels decreased markedly and the chylomicron fraction disappeared. Further studies may be necessary to determine if hypertriglyceridemic patients with or without apolipoprotein E4 show a greater reduction in serum TG levels with lipid-lowering agents.
AuthorsT Nagai, T Tomizawa, T Saito, T Nakano, K Nakajima, M Mori
JournalInternal medicine (Tokyo, Japan) (Intern Med) Vol. 35 Issue 5 Pg. 388-91 (May 1996) ISSN: 0918-2918 [Print] Japan
PMID8797053 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Apolipoprotein E3
  • Apolipoprotein E4
  • Apolipoproteins E
  • Chylomicrons
  • Hypolipidemic Agents
  • Lipoproteins, VLDL
  • Triglycerides
  • Heparin
  • Cholesterol
  • Lipase
  • Lipoprotein Lipase
  • Bezafibrate
Topics
  • Adult
  • Apolipoprotein E3
  • Apolipoprotein E4
  • Apolipoproteins E (blood, genetics)
  • Bezafibrate (therapeutic use)
  • Cholesterol (blood, chemistry)
  • Chylomicrons (blood)
  • Female
  • Heparin
  • Humans
  • Hyperlipoproteinemia Type V (blood, drug therapy, genetics)
  • Hypolipidemic Agents (therapeutic use)
  • Lipase (blood)
  • Lipoprotein Lipase (blood)
  • Lipoproteins, VLDL (blood)
  • Male
  • Phenotype
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: